Posts tagged Avivagen
Avivagen undertakes human health proof of concept

Avivagen (TSX-V:VIV), with the help of the National Research Council of Canada (NRC), will undertake a project to establish proof of concept for a first human health application of its OxC-beta technology.

Read More
Avivagen in JV for OxC-beta in China

Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China.

The JV will initially target OxC-beta for use in poultry and swine, with an option for use in cattle and goats (bovines and caprines).

Read More
Avivagen makes first industrial sale of OxC-beta

Avivagen (TSX-V:VIV) has made the first industrial-scale sale of its OxC-beta livestock to UNAHCO in the Philippines.

The sale is for 150 kilograms of OxC-beta livestock 10% premix at pricing in line with Avivagen's target. The order will supplement approximately 7.5 million kilograms of UNAHCO-branded commercial feed, an amount sufficient for about three million broiler chickens or 350,000 piglets.

Read More
Avivagen in OxC-beta pact with UNAHCO

Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines.

OxC-beta has been shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. Comprised of fully-oxidized beta-carotene, OxC-beta is a non-antibiotic means of maintaining optimal health and growth in livestock animals such as swine and poultry.

Read More
Avivagen, UNAHCO register OxC-beta in Philippines

Avivagen (TSX-V:VIV) and UNAHCO have registered OxC-beta Livestock as an imported livestock feed additive, authorizing its use in all species in the Philippines.

UNAHCO is a feed and veterinary unit of Unilab, the largest pharmaceutical company in the Philippines. UNAHCO provides a broad range of animal healthcare and nutrition products and programs to meet the requirements of both large commercial and smaller individual farmers in the Philippines as well as abroad.

Read More
Avivagen reports new livestock trials with OxC-beta

Avivagen (TSX-V:VIV) has provided results of four new trials of OxC-beta livestock as a feed additive for swine in the Philippines and Vietnam, and broiler poultry in the Philippines and Spain.

In a new trial with the National Institute of Animal Sciences for Vietnam, the use of OxC-beta significantly improved the major commercial parameters of average daily gain (ADG), final body weight (FBW), feed conversion ratio (FCR) and rates of diarrhea and mortality, compared with non-supplemented animals.

Read More
Avivagen closes private placement

Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.

Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.

Read More
Avivagen plans JV to sell OxC-beta in China

Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China.

The companies plan to create a Sino-Canadian joint venture company based in Xi’an, Shaanxi province, to register and commercialize OxC-beta Livestock, initially for use in poultry and swine.

Read More
Avivagen posts positive swine trial results in China

Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing.

The trial evaluated OxC-beta’s effect on growth efficiency and health of pigs raised under local conditions during the post-weaning “starter” period. OxC-beta enhanced growth in the “starter” pigs in this trial, a result consistent with previously-reported trials in swine and broiler poultry.

Read More
Avivagen begins trial of OxC-beta with UNAHCO

Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry.

Trial design reflects a collaboration between Avivagen and UNAHCO and it will measure the benefits of OxC-beta on the performance and welfare of broiler poultry raised under typical local commercial production conditions for their full growth cycle.

Read More
Avivagen starts OxC-beta Livestock trial with poultry

Avivagen (TSX-V:VIV) has started a new broiler poultry trial with the institute of agro-food research and technology of Catalonia, Spain.

The trial will test the efficacy of OxC-beta Livestock to enhance performance and welfare of healthy broiler chickens raised under typical production conditions. Subject to minor enhancements to the protocol, the trial is a replicate of the study conducted by the Spanish institute for Avivagen in 2015.

Read More
Avivagen issues letter to shareholders

In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans.

Mr. Groome said Avivagen continues the process of commercializing its non-antibiotic and naturally-occurring products, based on OxC-beta technology that, among their uses, are showing efficacy as a replacement for antibiotics in helping to maintain optimal health and growth in livestock.

Read More